Published in J Immunol on May 01, 1983
Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today (2008) 1.11
Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology (1989) 0.95
The acute phase response in parasite infection. Nippostrongylus brasiliensis in the mouse. Immunology (1984) 0.83
Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol (1995) 0.82
C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology (1987) 0.77
The role of phosphate groups in the interaction of human C-reactive protein with galactan polysaccharides. Immunology (1986) 0.75
C-reactive Protein and Disease Outcome in Nigerian Sickle Cell Disease Patients. Ann Med Health Sci Res (2014) 0.75
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia. Int Arch Allergy Appl Immunol (1967) 2.64
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol (1968) 2.38
Math5 encodes a murine basic helix-loop-helix transcription factor expressed during early stages of retinal neurogenesis. Development (1998) 2.38
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
Training physicians in counseling about smoking cessation. A randomized trial of the "Quit for Life" program. Ann Intern Med (1989) 2.07
The natural history of Peyronie's disease. J Urol (1990) 2.02
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J Pediatr (1976) 1.98
Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes (1999) 1.95
Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med (1976) 1.95
Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis). Medicine (Baltimore) (1970) 1.94
Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement. Proc Natl Acad Sci U S A (1969) 1.92
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother (1998) 1.91
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol (2001) 1.87
Interactions of the complement system with native and chemically modified endotoxins. J Bacteriol (1968) 1.87
Decreased properdin activity in acute glomerulonephritis. Int Arch Allergy Appl Immunol (1969) 1.83
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Xath5 participates in a network of bHLH genes in the developing Xenopus retina. Neuron (1997) 1.70
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. Am J Cardiol (1995) 1.69
C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Complement and complement-like activity in lower vertebrates and invertebrates. J Exp Med (1970) 1.61
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.61
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
Complement-dependent biological functions in complement deficiency in man. Lancet (1966) 1.56
Complement inactivation by serum from patients with acute and hypocomplementemic chronic glomerulonephritis. J Lab Clin Med (1968) 1.54
Some factors influencing the ability of anti-lymphocytic antibody to suppress humoral antibody formation. Clin Exp Immunol (1967) 1.52
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer (1994) 1.50
The genetic sequence of retinal development in the ciliary margin of the Xenopus eye. Dev Biol (1998) 1.49
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology (1974) 1.49
Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther (2012) 1.49
The preparation and properties of anti-lymphocytic sera. Prog Surg (1969) 1.48
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
Interactions of C-reactive protein with the first component of human complement. J Immunol (1977) 1.45
[Surgical treatment of the single non traumatic perforation of small bowel: excision-suture or resection-anastomosis]. Ann Chir (2005) 1.45
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44
Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol (2000) 1.43
Structure-property correlations in a combinatorial library of degradable biomaterials. J Biomed Mater Res (1998) 1.42
Training physicians about smoking cessation: a controlled trial in private practice. J Gen Intern Med (1990) 1.42
Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection. Acta Anaesthesiol Scand (1996) 1.42
Decreased C'-1q protein concentration and agglutinating activity in agammaglobulinaemia syndromes: an inborn error reflected in the complement system. Clin Exp Immunol (1968) 1.41
Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes. Infect Immun (1985) 1.41
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature (1967) 1.40
875 cases of bacterial meningitis: diagnostic procedures and the impact of preadmission antibiotic therapy. Part III of a three-part series. J Infect (1983) 1.40
Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol (1976) 1.39
Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med Microbiol Immunol (2001) 1.38
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol (1975) 1.37
Specific association of the proto-oncogene product pp60c-src with an intracellular organelle, the PC12 synaptic vesicle. J Cell Biol (1992) 1.37
Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg (1969) 1.37
Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet (1969) 1.36
Deficiency of C1r in human serum. Effects on the structure and function of macromolecular C1. J Exp Med (1970) 1.36
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
Complement in endotoxin shock: effect of complement depletion on the early hypotensive phase. Infect Immun (1970) 1.34
Which goal for fluid therapy during colorectal surgery is followed by the best outcome: near-maximal stroke volume or zero fluid balance? Br J Anaesth (2012) 1.33
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol (2000) 1.30
Deficiency of C7 with systemic lupus erythematosus: solubilization of immune complexes in complement-deficient sera. Arthritis Rheum (1981) 1.30
A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. J Immunol Methods (1993) 1.29
Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. Am Heart J (1995) 1.28
Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol (1987) 1.27
Interactions of the complement system with endotoxins from a Salmonella minnesota mutant deficient in O-polysaccharide and heptose. J Immunol (1968) 1.27
Characterization of antilymphocytic antibody. Nature (1967) 1.27
Complement and complement component activities in diseases associated with repeated infections and malignancy. Int Arch Allergy Appl Immunol (1968) 1.27
Activation and inhibition of IgG mediated complement fixation by staphylococcal protein A. Clin Exp Immunol (1970) 1.27
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol (1998) 1.27
Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness. Immunology (1977) 1.27
Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology (1975) 1.26
Characterization of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg (1993) 1.26
Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol (1987) 1.25
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation (1967) 1.25